Literature DB >> 9094622

Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase.

A Engelman1, Y Liu, H Chen, M Farzan, F Dyda.   

Abstract

Two different crystal structures of the human immunodeficiency virus type 1 (HIV-1) integrase (IN) catalytic domain were analyzed for interactions at the enzyme active site. Gln-62 and Glu-92 interact with active-site residue Asp-64, and Lys-136 interacts with active-site residue Asp-116 across a dimer interface. Conservative and nonconservative substitutions were introduced at these positions to probe the roles of these interactions in HIV-1 integration. Purified mutant proteins were assayed for in vitro 3' processing, DNA strand transfer, and disintegration activities, and HIV-1 mutants were assayed for virion protein composition, reverse transcription, and infectivities in human cell lines. Each of the mutant IN proteins displayed wild-type disintegration activity, indicating that none of the interactions is essential for catalysis. Mutants carrying Gln or Ala for Glu-92 displayed wild-type activities, but substituting Lys for Glu-92 reduced in vitro 3' processing and DNA strand transfer activities 5- to 10-fold and yielded a replication-defective IN active-site mutant viral phenotype. Substituting Glu for Gln-62 reduced in vitro 3' processing and DNA strand transfer activities 5- to 10-fold without grossly affecting viral replication kinetics, suggesting that HIV-1 can replicate in T-cell lines with less than the wild-type level of IN activity. The relationship between IN solubility and HIV-1 replication was also investigated. We previously showed that substituting Lys for Phe-185 dramatically increased the solubility of recombinant IN but caused an HIV-1 particle assembly defect. Mutants carrying His at this position displayed increased solubility and wild-type replication kinetics, showing that increased IN solubility per se is not detrimental to virus growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094622      PMCID: PMC191497     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types.

Authors:  E K Ross; A J Buckler-White; A B Rabson; G Englund; M A Martin
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

3.  Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus.

Authors:  S A Chow; K A Vincent; V Ellison; P O Brown
Journal:  Science       Date:  1992-02-07       Impact factor: 47.728

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.

Authors:  E O Freed; J M Orenstein; A J Buckler-White; M A Martin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Retroviral DNA integration directed by HIV integration protein in vitro.

Authors:  F D Bushman; T Fujiwara; R Craigie
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

7.  Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity.

Authors:  P A Sherman; J A Fyfe
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

8.  Single-step purification of bacterially expressed polypeptides containing an oligo-histidine domain.

Authors:  M W Van Dyke; M Sirito; M Sawadogo
Journal:  Gene       Date:  1992-02-01       Impact factor: 3.688

9.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.

Authors:  F W Studier; B A Moffatt
Journal:  J Mol Biol       Date:  1986-05-05       Impact factor: 5.469

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  41 in total

1.  Ty3 integrase is required for initiation of reverse transcription.

Authors:  M Henrietta Nymark-McMahon; Nadejda S Beliakova-Bethell; Jean-Luc Darlix; Stuart F J Le Grice; Suzanne B Sandmeyer
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Correlation of recombinant integrase activity and functional preintegration complex formation during acute infection by replication-defective integrase mutant human immunodeficiency virus.

Authors:  Xiang Li; Yasuhiro Koh; Alan Engelman
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants.

Authors:  Matthew C Lee; Jinxia Deng; James M Briggs; Yong Duan
Journal:  Biophys J       Date:  2005-02-24       Impact factor: 4.033

4.  Human immunodeficiency virus type 1 and related primate lentiviruses engage clathrin through Gag-Pol or Gag.

Authors:  Sergei Popov; Bettina Strack; Victor Sanchez-Merino; Elena Popova; Heike Rosin; Heinrich G Göttlinger
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

5.  Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors.

Authors:  Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Mutational scan of the human immunodeficiency virus type 2 integrase protein.

Authors:  F M van den Ent; A Vos; R H Plasterk
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Replication of chimeric human immunodeficiency virus type 1 (HIV-1) containing HIV-2 integrase (IN): naturally selected mutations in IN augment DNA synthesis.

Authors:  Marcus Padow; Lilin Lai; Champion Deivanayagam; Lawrence J DeLucas; Robert B Weiss; Diane M Dunn; Xiaoyun Wu; John C Kappes
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex.

Authors:  X Wu; H Liu; H Xiao; J A Conway; E Hehl; G V Kalpana; V Prasad; J C Kappes
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Augmentation of reverse transcription by integrase through an interaction with host factor, SIP1/Gemin2 Is critical for HIV-1 infection.

Authors:  Hironori Nishitsuji; Takaya Hayashi; Takuya Takahashi; Masashi Miyano; Mari Kannagi; Takao Masuda
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

10.  Specificity of LTR DNA recognition by a peptide mimicking the HIV-1 integrase {alpha}4 helix.

Authors:  Zeina Hobaika; Loussine Zargarian; Yves Boulard; Richard G Maroun; Olivier Mauffret; Serge Fermandjian
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.